Novartis backs away from once-ambitious RNAi research

Novartis ($NVS) is shuttering a large part of its once-ambitious RNAi research effort in Boston, FierceBiotech has learned. The pharma giant, which has extensive R&D operations in the Boston area, confirmed the move, saying that the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move. Report